Neurosense Therapeutics is trading 8.49% higher at $1.39, with no clear company-specific announcement identified to explain the November 4 move. - The latest identified company release, dated November 2, said biomarker data would be added to PrimeC’s Canadian submission and the target filing shifted to March 2027. - The supplied context reports XBI up 2.13%, alongside gains in major U.S. indexes, consistent with a strong biotech-sector session. This does not establish a specific catalyst for the stock’s larger move.